查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1620415

Alpha-1 抗胰蛋白酶缺乏症治疗市场机会、成长驱动因素、产业趋势分析与预测 2024 - 2032 年

Alpha-1 Antitrypsin Deficiency Disease Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 114 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球Alpha-1 抗胰蛋白酶缺乏症治疗市场价值为26 亿美元，预计2024 年至2032 年复合年增长率为10.1%。推动的、提高意识、加强筛检计画以及诊断和治疗方案的进步。市场扩张的一个重要推动因素是慢性阻塞性肺病 (COPD)、肝硬化和其他与 AATD 相关的併发症的发病率不断增加。随着受这些疾病影响的人数不断增加，对有效治疗方案的需求也不断增加。市场也受益于更大的意识努力和改善患者治疗效果的尖端治疗方法的开发。

就治疗类型而言，市场分为药物、疗法和手术介入。药物细分市场包括 α-1 蛋白酶抑制剂、支气管扩张剂和皮质类固醇，在 2023 年占据市场主导地位，销售额达 19 亿美元。药物在控制 AATD 患者的症状和预防肺气肿和慢性阻塞性肺病等肺部疾病的进展方面发挥着至关重要的作用。该市场按给药途径进一步分类，到2023 年，肠胃外途径将占据58.1% 的显着份额。立即缓解治疗的患者至关重要。

从地理上看，北美预计将成为市场成长的主要贡献者，预计到 2032 年复合年增长率为 9.8%。美国人口老化，更容易患上 AATD 相关疾病，进一步推动了对先进治疗的需求

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 26亿美元
预测值 62 亿美元
复合年增长率 10.1%

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • α-1 抗胰蛋白酶缺乏症 (AATD) 盛行率不断增加
      • 生物技术的进步
      • AATD 新疗法获批
    • 产业陷阱与挑战
      • 治疗费用高
      • 与治疗相关的不良反应
  • 监管环境
  • 管道分析
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021-2032 年

  • 主要趋势
  • 药物
    • Alpha-1蛋白酶抑制剂
    • 支气管扩张剂
    • 皮质类固醇
    • 其他药物
  • 治疗
    • 强化治疗
    • 氧气治疗
    • 其他疗法
  • 手术

第 6 章：市场估计与预测：按管理途径，2021-2032 年

  • 主要趋势
  • 注射用
  • 鼻内
  • 口服

第 7 章：市场估计与预测：按年龄划分，2021-2032

  • 主要趋势
  • 儿科
  • 成人

第 8 章：市场估计与预测：依最终用途，2021-2032 年

  • 主要趋势
  • 医院
  • 专科诊所
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Arrowhead Pharmaceuticals, Inc.
  • CHIESI Farmaceutici SpA
  • CSL Behring
  • Epicrispr Biotechnologies, Inc.
  • GlaxoSmithKline plc
  • Grifols SA
  • Intellia Therapeutics, Inc.
  • Kamada Pharmaceuticals
  • Mayo Foundation for Medical Education and Research.
  • National Jewish Health
  • Shire plc (Takeda Pharmaceutical Company Limited)
  • The General Hospital Corporation
  • The Johns Hopkins Hospital
简介目录
Product Code: 11707

The Global Alpha-1 Antitrypsin Deficiency Disease Treatment Market was valued at USD 2.6 billion in 2023 and is expected to grow at a CAGR of 10.1% between 2024 and 2032. This growth is fueled by the rising prevalence of AATD-related respiratory and liver conditions, increased awareness, enhanced screening programs, and advancements in diagnostic and therapeutic options. A significant driver of the market expansion is the increasing incidence of chronic obstructive pulmonary disease (COPD), liver cirrhosis, and other complications associated with AATD. As the number of individuals affected by these conditions grows, so does the demand for effective treatment options. The market is also benefiting from greater awareness efforts and the development of cutting-edge treatments that improve patient outcomes.

In terms of treatment types, the market is segmented into medications, therapies, and surgical interventions. The medication segment, which includes alpha-1 proteinase inhibitors, bronchodilators, and corticosteroids, dominated the market in 2023, accounting for USD 1.9 billion. Medications play a crucial role in managing symptoms and preventing the progression of lung diseases like emphysema and COPD in patients with AATD. The market is further categorized by route of administration, with the parenteral route holding a significant share of 58.1% in 2023. Parenteral administration is important for delivering medications directly into the bloodstream, ensuring rapid absorption and effectiveness-essential for patients needing immediate therapeutic relief.

Geographically, North America is expected to be a key contributor to the market growth, with a projected CAGR of 9.8% through 2032. The region's growth is primarily driven by advancements in therapeutic interventions and a high prevalence of AATD. The aging population in the U.S., which is more prone to AATD-related conditions, further propels the demand for advanced treatments

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$2.6 Billion
Forecast Value$6.2 Billion
CAGR10.1%

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of alpha-1 antitrypsin deficiency disease (AATD)
      • 3.2.1.2 Advancements in biotechnology
      • 3.2.1.3 Approval of novel therapies for AATD
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of treatment
      • 3.2.2.2 Adverse effects associated with treatment
  • 3.3 Regulatory landscape
  • 3.4 Pipeline analysis
  • 3.5 Future market trends
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021-2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Medication
    • 5.2.1 Alpha-1 proteinase inhibitor
    • 5.2.2 Bronchodilators
    • 5.2.3 Corticosteroids
    • 5.2.4 Other medications
  • 5.3 Therapy
    • 5.3.1 Augmentation therapy
    • 5.3.2 Oxygen therapy
    • 5.3.3 Other therapies
  • 5.4 Surgery

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021-2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Parenteral
  • 6.3 Intranasal
  • 6.4 Oral

Chapter 7 Market Estimates and Forecast, By Age Group, 2021-2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Pediatric
  • 7.3 Adult

Chapter 8 Market Estimates and Forecast, By End Use, 2021-2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Specialty clinics
  • 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Arrowhead Pharmaceuticals, Inc.
  • 10.2 CHIESI Farmaceutici S.p.A.
  • 10.3 CSL Behring
  • 10.4 Epicrispr Biotechnologies, Inc.
  • 10.5 GlaxoSmithKline plc
  • 10.6 Grifols S.A.
  • 10.7 Intellia Therapeutics, Inc.
  • 10.8 Kamada Pharmaceuticals
  • 10.9 Mayo Foundation for Medical Education and Research.
  • 10.10 National Jewish Health
  • 10.11 Shire plc (Takeda Pharmaceutical Company Limited)
  • 10.12 The General Hospital Corporation
  • 10.13 The Johns Hopkins Hospital